European generics firms, squeezed between innovators and payers, seek diversity
This article was originally published in SRA
Mixed sentiments about the future of the European generic medicines sector were in evidence at the annual meeting of the European Generic medicines Association in Lisbon on 16-17 June1. Upbeat forecasts from industry figures contrasted with a more downbeat assessment from some consultancy firms in the face of the innovation slowdown, competition from R&D firms and the challenges posed by the biosimilars market.
You may also be interested in...
The team behind Russia’s first COVID-19 vaccine has asked for scientific advice from EU drug regulators in view of a possible submission for marketing authorization.
The number of new drugs containing new active substances approved in the EU rose significantly in 2020, underpinned by a strong showing for orphan-designated products and a string of novel medicines for cancer and infectious diseases. Notable among the new clutch of approvals was the first ever COVID-19 vaccine, Pfizer/BioNTech's Comirnaty.
Coronavirus Notebook: EMA Data Hack Aimed At 'Undermining Trust' In Vaccines, Russia Plans EU Sputnik V Filing Next Month
France has reported on side-effect reports concerning the Pfizer/BioNTech vaccine, and the World Health Organization has warned that plans to provide global equitable access to coronavirus vaccines are at risk.